Announcement PDF ASX Announcement AGM Chair address and CEO presentation Melbourne, Australia; 6 November 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today provides a copy of the Chair’s address and CEO’s presentation, which will be presented at the Annual General Meeting (AGM) of Starpharma Holdings Limited, starting at 1:00 pm (Melbourne time) today. About Starpharma Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, Chief Financial and Operations Officer and Company Secretary +61 3 8532 2700 investor.relations@starpharma.com Level 3, 40 River Boulevard Richmond VIC 3121 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. 2 Starpharma Holdings Limited Annual General Meeting 6 November 2026 Chair’s address to shareholders Welcome Good afternoon, fellow shareholders. Welcome to Starpharma’s 2026 Annual General Meeting. On behalf of the Board, thank you for joining us and for your continued support of the company. I am addressing you today for the final time as Chair. It has been a privilege to serve in the role for 12 years. During that time, Starpharma has launched products, formed partnerships with global companies and pursued innovation across oncology and other areas of significant unmet medical need. The company has also continued to demonstrate the value and potential of its dendrimer technology. The past two years have been very important for Starpharma, with the transition of our CEO and a renewed strategic focus. The company has advanced our lead radiopharmaceutical program, strengthened the external validation of our DEP® platform through new partnership opportunities and improved the company’s financial position with a net $30 million rights offer. Together, these achievements have created a stronger foundation for future clinical, commercial and partnering opportunities. With these key items completed, the time is right for me to step down as Chair. Subject to shareholder approval today, I look forward to continuing as a director and supporting an orderly Chair transition to Dr Russell Basser. A focused strategy for value creation Starpharma’s strategy centres on applying our proprietary dendrimer technology where it can deliver clear differentiation and meaningful value. We have continued to refine our focus. Today, our primary focus is targeted oncology, including radiopharmaceuticals. These are areas where drug delivery, biodistribution and off-target toxicity remain significant challenges. The DEP® technology is an important strategic platform that provides multiple potential pathways to value creation through proprietary programs, strategic collaborations and licensing opportunities. The integration of AI is also providing efficiencies and expanding our ways of working. Advancing DEP® HER2-Lu towards the clinic A major priority this year was advancing DEP HER2-Lu, our lead proprietary radiopharmaceutical candidate. Cheryl will provide a more detailed update shortly. The Board has been very pleased with the intensity, rigour, and agility the team has shown in moving this program from research towards clinical development. 3 We are encouraged by the preclinical results to date. We are also encouraged by feedback from key opinion leaders and clinicians. Together, this gives us confidence that we are progressing a differentiated product candidate which can add real value. The program represents an important opportunity to demonstrate the potential of DEP® in a high- value and rapidly evolving area of precision oncology. Strategic partnerships and external validation Partnerships remain central to our strategy. They enable external organisations to apply DEP® to their own programs. They broaden the number of opportunities being progressed. They also create potential pathways to research revenue, upfront payments, milestones and royalties. A major achievement in FY26 was executing the Collaboration and License Agreement with Genentech. The agreement included an $8.3 million upfront payment, up to $804 million in potential success- based milestones plus tiered royalties on global net sales. Beyond its economic potential, the collaboration places DEP® within the development pipeline of a global oncology leader. It also provides important external recognition of the platform’s capabilities. The agreement has increased Starpharma’s visibility and helped open doors to other potential opportunities. We also partnered with Radiopharm Theranostics to support the development of one of their assets. This program advanced rapidly during the year. Once again, our team demonstrated its ability to collaborate effectively and operate with speed and agility. More recently, we increased our ownership in Petalion Therapeutics to a majority stake, building on two years of collaboration with Medicxi. This allows us to share more about the oncology program which targets FAP – a promising target with potential relevance across multiple cancer types. The Board and Leadership team are excited to continue the strong collaboration with Medicxi, and to lead the next phase of development for this program. Commercial portfolio and financial position Whilst the company increases its focus on targeted oncology, our marketed products – Viraleze and VivaGel BV – continue to provide revenue and commercial optionality. Following the end of the financial year, we successfully raised net proceeds of $30 million. The approximately 99 per cent uptake demonstrated strong support from existing shareholders. On behalf of the Board, I sincerely thank everyone who participated, especially the underwriters who supported the raise. The funds strengthen Starpharma’s balance sheet, extend our funding runway into FY28, and support continued execution of our priority oncology programs. People and culture Starpharma’s progress is made possible by the quality and commitment of its people. 4 Our partners consistently recognise the team’s expertise, responsiveness and collaborative approach. And we remain focused on recruiting the right capabilities, strengthening a culture of collaboration and accountability, and building high-performing teams. This is essential as our programs become more complex and our engagement with global partners expands. This culture was recently recognised by Great Place to Work. Starpharma ranked seventh in Australia’s 2026 Best Workplaces in Biotechnology and Pharmaceuticals list. This is a wonderful achievement. On behalf of the Board, I thank our CEO, Cheryl Maley, for her leadership. I also thank the entire team for their dedication, adaptability and disciplined execution, especially the alchemists whom we call chemists who work wonders with these dendrimers. I also thank my fellow directors for their guidance, commitment and contribution. Looking ahead Finally, I thank shareholders for the support you have shown me during my 12 years as Chair. There have been challenges and achievements. Highs and lows. Throughout, I have remained proud of the company’s purpose, its people and its determination. This company has such an exciting future. Today, I pass the baton to Russell Basser. Russell, with his broad experience in oncology and clinical trials, will be an excellent Chair and of immense help to Cheryl and her team in this coming phase of our development. Subject to your approval, I look forward to continuing as a director and supporting the transition. The Board and leadership team remain committed to disciplined decisions, prudent capital allocation and transparent communication. We work extraordinarily well together. Our focus is on converting Starpharma’s technology and partnerships into meaningful outcomes. Starpharma enters this next phase with a differentiated platform, a stronger balance sheet, growing external validation and a focused and capable team. Most importantly, we remain guided by a clear purpose: to apply our dendrimer technology to help improve treatment options and outcomes for patients. To our shareholders, thank you for your continued trust and support. We recognise the importance of delivering sustainable value, and we remain focused on the milestones and opportunities that can best unlock the long-term potential of DEP®. On behalf of the Board, and one final time as Chair, thank you for your ongoing support of Starpharma. Rob Thomas, AO Chair I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Starpharma Holdings Limited (ASX:SPL) (US OTC:SPHRY) A n n u a l G e n e r a l M e e t i n g 6 November 2026 This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 Disclaimer and Forward-Looking Statements A N N U A L G E N E R A L M E E T I N G 2 0 2 6 3 Our Mission and Purpose Redefining cancer treatment with dendrimer science A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Our mission Help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 4 The Road to the Patient A complex journey that requires many connected steps, different areas of expertise, and a shared commitment to patients A N N U A L G E N E R A L M E E T I N G 2 0 2 6 5 2025-26 Operational Highlights Significant progress across the DEP® platform, strategic partnerships and radiotheranostics pipeline A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Strategic validation & partnering Genentech Strategic collaboration & licence Radiopharm Theranostics Research & option agreement; option period triggered Petalion Therapeutics First stage of R&D completed; increased equity Star Navigator International partnering engagement DEP® SN38 & cabazitaxel Phase 2 results published in peer-reviewed journals Research & development DEP® HER2-Lutetium Positive preclinical data + FDA feedback New radioligand targets Encouraging data support broader DEP® potential Discovery program Building a targeted oncology pipeline Sustainable operations Commercial growth New Viraleze and VivaGel® BV distribution arrangements Record online sales Viraleze up 55% year-on-year Great Place to Work® Certification & Top 10 Ranking Fourth consecutive certification; ranked #7 in Pharmaceuticals & Biotechnology During the year, Starpharma negotiated and executed 3 material agreements and increased its focus on its targeted oncology pipeline. FROM Building and validating a versatile dendrimer platform DEP® BREADTH CREATED THE FOUNDATION Expertise • Clinical validation • IP • Partnerships DISCIPLINED PRIORITISATION Highest-value opportunities TO A focused targeted oncology company Applying DEP® where differentiated delivery can create the greatest patient and shareholder value TARGETED ONCOLOGY 01 Priority oncology assets DEP® HER2-Lu lead program Targeted radiopharmaceutical pipeline 02 Validated DEP® platform Clinical experience and external validation through partnerships Modular oncology applications 03 Focused value creation Advance, partner and commercialise Disciplined portfolio allocation FOCUS WILL DRIVE THE NEXT PHASE OF VALUE CREATION 7 From Broad Platform Validation to Focused Oncology Value Creation Two decades of dendrimer expertise are now being concentrated on high-value targeted oncology opportunities A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Antivirals Consumer health Oncology Diagnostics Women’s health 6 Two Complementary DEP® Approaches to Drive Shareholder Value Building value through proprietary assets and strategic partnerships A N N U A L G E N E R A L M E E T I N G 2 0 2 6 DEP® PLATFORM One platform enabling multiple commercial pathways OWN AND ADVANCE Proprietary assets Build differentiated DEP® oncology assets in selected high value therapeutic areas. VALUE: asset ownership • partnering • commercialisation COLLABORATE AND SCALE Strategic partnerships Apply DEP® with pharmaceutical, biotechnology and investment partners across a broader range of opportunities. VALUE: licences • milestones • R&D funding • royalties • strategic exits A balanced model combining the upside of asset ownership with the reach, validation and economics of strategic partnerships. 7 Evolving Asset Pipeline Strategic focus on targeted therapies and partnerships in oncology to drive shareholder value Product Target Indication Pre- clinical Phase 1 Phase 2 Phase 3 Status Targeted Therapies DEP® HER2-Lutetium DEP® FAP-targeted asset Other DEP® oncology assets Non-Targeted Therapies DEP® SN38 DEP® cabazitaxel Ovarian and colorectal Prostate and gastro-oesophageal HER2+ cancers, including gastric Various Entering Phase I Partner Pipeline Combined $1B+deal value Partner Therapeutic area Oncology Oncology (radiopharmaceuticals) Clinical results reported Clinical results reported Partner-ready^ Partner-ready^ ^Ongoing business development activity; supported by external advisors. Pan-cancer 8 A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Disciplined Discovery Pipeline of Proprietary DEP® Assets Focusing capital where patient need, platform advantage and value potential align A N N U A L G E N E R A L M E E T I N G 2 0 2 6 HIGH UNMET NEED Meaningful patient need and scope for clinically relevant differentiation CLEAR DEP® ADVANTAGE A defined role for DEP® in improving targeting, delivery or therapeutic performance ATTRACTIVE VALUE POTENTIAL Strong scientific rationale, commercial relevance and a credible development pathway Highest growth targeted oncology modalities Radiopharmaceuticals Targeted delivery of radioisotopes Drug conjugates Targeted delivery of potent payloads; ability for high drug loading; flexibility for multi-payloads RNA therapeutics Including targeted delivery of siRNA and other oligonucleotides Other targeted therapies Selective opportunities meeting the criteria above Focused deployment of capital where DEP® can create differentiated assets and meaningful shareholder value. 9 DEP® HER2-Lu – Targeted Radioligand Therapy Leveraging Dendrimer Technology First-in-class HER2 Radiotherapy DEP® HER2-lutetium Optimised Design: Parameter Target Product Profile Tumour Uptake Fast tumour accumulation Tumour Retention Retention in tumour >48h Renal Clearance Fast clearance, minimal accumulation Blood Clearance Effective clearance from blood / bone marrow by 48h Efficacy HER2high and HER2low expressing tumours Indications HER2 expressing cancers (gastroesophageal, breast, etc.) HER2-targeting nanobody (VHH) Surface PEG DOTA-Lutetium-177 DEP® Dendrimer Scaffold DEP® HER2-lutetium Schematic Differentiated profile with potential to enhance tumour targeting and tolerability A N N U A L G E N E R A L M E E T I N G 2 0 2 6 10 11 DEP® HER2-Lu Program Status First-in-human Phase 1 study to commence in December 2026 subject to ethics approval A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Regulatory milestones FDA type C meeting complete; ethics approval pending Clinical manufacturing Inhouse manufacture and Radiopharmacy set-up Site preparations Operational start-up towards patient recruitment Clinical trial application under review Regulatory / ethics approval anticipated in CY26 Enables first-in-human Phase 1 dosing European (Netherlands) research hub draws on world-leading HER2 oncology and imaging expertise Working with University Medical Center Groningen Site preparations continuing alongside regulatory / ethics review Clinical manufacturing and radiopharmacy advanced Manufacture of non-radiolabelled dendrimer precursor completed DEP® HER2-Lu radiolabelling process development, optimisation, validation and quality control methods completed for the Phase 1 study T = SKOV3 (HER2+) tumour K = kidneys DEP® HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Strong tumour uptake and prolonged tumour retention with low kidney exposure A N N U A L G E N E R A L M E E T I N G 2 0 2 6 2D SPECT imaging showing actual radiation signal (intensity) over time (Images not corrected for decay). SKOV3 is a HER2-high expressing cancer cell line. Mice (n=3 per group) dosed with 15 MBq of radioactivity. One representative mouse is shown per group per timepoint. DEP® HER2-Lu vs. radiolabelled HER2-targeting VHH without dendrimer, HER2-VHH-Lu 4 hours T DEP® HER2-Lu T HER2-VHH-Lu 48 hours T T K K 5 days T T 12 days T T K DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu 12 0 48 96 144 192 240 288 0 10 20 30 40 50 Time post-dose (hours) Radioactivity (%ID/g) Ex vivo biodistribution, SKOV3 tumour-bearing mice, n=3 per timepoint dosed with 15 MBq radioactivity; ID/g = injected dose (radioactivity) per gram of tissue; data are mean ± SEM DEP® HER2-Lu Blood Clearance Fast clearance from blood (%ID/g) Ratio in Tumour vs. Tissue 48 hours 5 days 12 days (%ID/g) 48 hours 5 days 12 days Strong tumour uptake and prolonged retention Low kidney exposure DEP® HER2-Lu Biodistribution Tumour radioactivity ~150 times higher than blood Radioactivity in the tumour vs: DEP® HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Fast blood clearance, minimal kidney exposure and favourable tumour to tissue ratios A N N U A L G E N E R A L M E E T I N G 2 0 2 6 13 0 10 20 30 40 50 60 0 20 40 60 80 100 Time post-dose (Days) Survival (%) *** * ** DEP® HER2-Lutetium Achieves Significant Anti-tumour Activity & Survival Benefits Durable tumour growth control and survival benefits that are comparable to Enhertu® A N N U A L G E N E R A L M E E T I N G 2 0 2 6 0 10 20 30 40 50 0 500 1000 1500 Time post-dose (Days) Tumor volume (mm 3 ) *** Mice (n=8 per group) dosed IV on Day 0. SKOV3 is a HER2-high expressing cancer cell line. Tumour volume curves displayed until volume of tumour in the first mouse in each group reaches volume endpoint (1500 mm3). Study terminated Day 57. Tumour volume data are mean ± SEM and analysed by ordinary one-way analysis of variance (ANOVA) with Dunnett’s multiple corrections on tumour growth inhibition(Day 21-Day 0) at Day 21. ***P<0.001 for DEP® HER2-Lu (15 and 25 MBq) and T- DXd (Enhertu®) vs Vehicle (phosphate buffered saline, PBS) and HER2-VHH-Lu. Survival data are analysed by Logrank (Mantel-Cox) test between two groups. *P<0.05, **P<0.01 and ***P<0.001 for each group vs. Vehicle and HER2-VHH-Lu. Anti-tumour Activity Survival Benefit DEP® HER2-Lu (25 MBq) DEP® HER2-Lu (25 MBq) 50% survival @d57 Enhertu® (10 mg/kg) 12.5% survival @d57 HER2-positive (high-expressing) cancer model; DEP® HER2-Lu (25 MBq) and DEP® HER2-Lu (15 MBq) vs. Enhertu®, HER2-VHH-Lu and Vehicle (PBS, saline) 14 15 DEP® HER2-Lu Clinical Development Strategy Significant unmet need offers potential for Accelerated Approval A N N U A L G E N E R A L M E E T I N G 2 0 2 6 FIH / Phase 1 (Imaging, dosimetry, and mass dose determination – Up to 15 patients) Phase 1/2 (Dose escalation/confirmation, expansion cohorts, efficacy, safety, up to 40 patients) Pivotal Study Phase 2/3 (Registrational, potential Fast Track – up to 250 patients) FDA Type B Pre-IND Meeting Registration H2 CY26 Study to commence following ethics approval H2 CY27 Topline readout for up to 15 patients from FIH/Ph 1 Ph 1/2 (IND) begins H1 CY27 Initial data readout First 3-4 patients CY28 Phase 2/3 ready POTENTIAL FOR ACCELERATED APPROVAL Objectives • Confirm tumour targeting • Optimise mass-dose and biodistribution • Assess safety, PK and dosimetry Endpoints • PK and tumour uptake • Biodistribution / dosimetry • Safety & tolerability Next Steps • First patient dosed • Initial data H1 CY27 • Topline Phase 1 data H2 CY27 • Pre-IND/IND • Advance to Phase 1/2 expansion cohorts First-in-human Phase 1 Clinical Study 16 DEP® Benefits Extend Across Radioligand Targets Focused preclinical work in HER2, PSMA and EGFR to show the dendrimer advantage is not target-specific A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Consistent tumour uptake across HER2-, PSMA- and EGFR-targeted DEP® constructs Consistent DEP® profile across different tumour targets Favourable tumour-to-tissue ratios across key healthy tissues Supports the engineered DEP® profile: strong tumour retention with low off-target exposure Well tolerated in preclinical studies Stable body-weight data are consistent with the favourable biodistribution and tolerability findings HER2 Lead asset: DEP® HER2-Lu PSMA Preclinical DEP® data EGFR Preclinical DEP® data DEP® performs consistently across targets, supported by Starpharma’s radioligand therapy patent filing Partnering and Business Development Converting DEP® technology into partner-funded value across oncology and radiotheranostics A N N U A L G E N E R A L M E E T I N G 2 0 2 6 Partnering Strategy Out-license and co-develop DEP® assets with partners who fund development. Starpharma generates value through milestones, royalties and, where relevant, equity. Capital-efficient pipeline expansion with clear IP boundaries and defined fields of use. Strategic Partnerships Joint Venture Star Navigator Phase 2 Ready Assets A$8.3m upfront received A$806m (US$564m) milestone potential A$91m upfront and milestone potential Majority owned strategic partnership FAP-targeted oncology program Single target focus Partner-led DEP® value creation Structured access for biotech and pharma groups Targeted engagement at international sector and partnering conferences DEP® SN38 & Cabazitaxel 2 assets in active partner outreach Published Phase 2 data show encouraging activity and tolerability in hard-to-treat cancers, supporting partner discussions 17 Petalion: Greater Ownership, Greater Value Stake up from 22.5% to 66%, advancing a FAP-targeted DEP® oncology program A N N U A L G E N E R A L M E E T I N G 2 0 2 6 18 Important Strategic Step WHY IT MATTERS FOR STARPHARMA VALUE FOR SHAREHOLDERS Portfolio: adds a FAP-targeted dendrimer-drug conjugate to Starpharma’s focused DEP® oncology portfolio. Validation: FAP is a high-value, externally validated target and early data are encouraging. Partner: Medicxi remains a 30% strategic shareholder, adding oncology-development and partnering expertise. Leadership: key next phase relies on Starpharma’s R&D strengths, with two Starpharma-appointed directors and the Starpharma CEO as Board Chair. Greater share of upside: 66% ownership, up from 22.5%, gives majority economic ownership of the program. Large market: FAP is a pan-cancer target (pancreatic, lung, breast and others) with multi-billion-dollar potential. Disciplined funding: up to A$5.0m, with A$3.0m cash from the capital raise allocation for new R&D pipeline opportunities. Clear next step: lead candidate selection to define the development and partnering pathway. FAP Targeted Dendrimer Conjugate ■ Starpharma 66% ■ Medicxi 30% ■ Petalion advisers 4% Petalion becomes a UK-incorporated subsidiary of Starpharma Holdings Ltd. Starpharma now controls Petalion’s FAP program and most of its upside, backed by Medicxi. FAP: A High-Value Target with a Clear 12-Month Path DEP® delivery aims to turn a validated stromal target into an IND-ready lead A N N U A L G E N E R A L M E E T I N G 2 0 2 6 1 Why FAP matters • Pan-cancer stromal target: pancreatic, breast, sarcoma, colorectal and lung • Low expression in healthy adult tissue • Multi-billion-dollar potential across indications 2 The delivery challenge • Remain stable in circulation • Release payload locally • Reach adjacent cancer cells • Stromal uptake alone is insufficient 3 How DEP® helps • Designed to improve stromal tumour penetration and retention in the tumour microenvironment • Designed to minimise off-target toxicity Work to date • Extensive constructs designed & tested in vitro & in vivo • Early data encouraging and supports program moving into the next phase Next 12 months Payloads and candidates flagged for lead selection Complete pre-clinical program Lead candidate selected Disciplined funding: up to A$5.0m behind the Petalion program 19 Genentech Collaboration and License Agreement Collaboration overview, financial terms and strategic significance A N N U A L G E N E R A L M E E T I N G 2 0 2 6 20 About Genentech Considered the founder of the biotech industry and now a member of the Roche Group, Genentech has been delivering on the promise of biotechnology for 50 years Pioneering pharmaceutical innovation Discovered the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. A community of changemakers 50 years of working to solve unmet medical needs. Staff of 12.1K people. Partnering to solve complex health challenges 250+ ongoing collaborations around the world. Strong product pipeline Around 70 new investigational medicines in clinical development and approximately 250 active clinical trials in the United States. Collaboration Overview Starpharma employing its proprietary DEP® platform technology to develop dendrimer- drug conjugates that incorporate Genentech medicines for certain oncology targets. Genentech has an exclusive worldwide license under Starpharma’s IP to commercialise products resulting from the parties’ collaboration. Genentech will be responsible for all development and commercialisation of products resulting from the collaboration, which could include multiple products for each target. Financial Terms Upfront payment A$8.3 million Received in October 2025 Success-based milestones Up to A$806 million (USD $564 million) Starpharma is also eligible for tiered royalties on global net sales of products resulting from the collaboration. Strategic Significance for Starpharma Recognises the poten